Kliniken Ostalb gemeinnuetzige kommunale Anstalt des oeffentlichen Rechts
- Address
- Im Kaelblesrain 1, 73430 Aalen, Germany
Kliniken Ostalb - Hematologic Malignancies Research Center
Kliniken Ostalb gemeinnuetzige kommunale Anstalt des oeffentlichen Rechts is a distinguished public healthcare institution specializing in advanced clinical research for hematologic malignancies. The center demonstrates particular expertise in conducting phase 2 and phase 3 trials evaluating novel therapeutic approaches for blood disorders and lymphomas, with a focus on improving outcomes for patient populations with limited treatment options.
- Myelodysplastic Syndrome (MDS) research, particularly investigating oral azacitidine therapy for IPSS-R low- or intermediate-risk patients
- Diffuse Large B-Cell Lymphoma (DLBCL) treatment optimization in older adults using combination immunochemotherapy regimens
- Targeted therapy development with novel agents including BTK inhibitors and epigenetic modulators
The research center plays a vital role in evaluating treatment strategies for older adult populations who may not be candidates for standard intensive therapies. Through participation in multicenter international trials, Kliniken Ostalb contributes to advancing personalized medicine approaches in hematologic oncology, with particular attention to optimizing dose regimens and combination therapies that balance efficacy with safety profiles suitable for elderly and frail patient populations.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 1 by active trials.
- 1University Of Saarland1active
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Kliniken Ostalb gemeinnuetzige kommunale Anstalt des oeffentlichen Rechts
lock Showing 1 of 2 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 2/3, Multicenter, Randomized, Dose Optimization (Part I), Double-blind (Part II) Study to Compare the Efficacy and Safety of Oral Azacitidine (Oral-Aza, ONUREG®) plus Best Supportive Care (BSC) versus Placebo plus BSC in Participants with IPSS-R Low- or Intermediate-risk Myelodysplastic Syndrome (MDS) | Celgene Corp. | Phase IV | Not Recruiting | Mar 2023 | — |
IMP list
lock Showing 1 of 9 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Acalabrutinib | 1 | Unknown | 2023-04-24 | 2023-04-24 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.